Table 5.

Biomarker-based staging and prognosis in ATTR amyloidosis

Model	Type	Biomarker, cut-off	Stages	Estimated median OS (months)
Kristen et al.57	ATTRwt and ATTRv	NT-proBNP >2584 ng/L (or BNP >195 ng/L) TnT >50 ng/L (or TnI >580 ng/L)	A: 2 >cut-offs	40% alivea
			B: 2 <cut-offs	98% alivea
			C: 1 >cut-off	80% alivea
Grogan et al.58	ATTRwt	NT-proBNP ≥3000 ng/L TnT ≥50 ng/L	I: both below the cut-offs	66
			II: 1 above the cut-off	40
			III: both above the cut-offs	20
Gillmore et al.56	ATTRwt and ATTRv	NT-proBNP >3000 ng/L eGFR <45 mL/min/1.73 m2	I: both below the cut-offs	69
			II: 1 above the cut-off	47
			III: both above the cut-offs	24

ATTRwt, wild-type transthyretin amyloidosis; ATTRv; variant transthyretin amyloidosis; BNP, B-type natriuretic peptide; eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal fraction of pro–B-type natriuretic peptide; (hs-) TnT, (high-sensitivity) troponin T; (hs-)TnI, (high-sensitivity) troponin I.

3-year survival estimate.